Hubbry Logo
Charles WeissmannCharles WeissmannMain
Open search
Charles Weissmann
Community hub
Charles Weissmann
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Charles Weissmann
Charles Weissmann
Charles Weissmann
View on Wikipedia
from Wikipedia

Charles Weissmann (14 October 1931 – 11 December 2025) was a Hungarian-Swiss molecular biologist. Weissmann is particularly known for the first cloning and expression of interferon [1][2] and his contributions to the unraveling of the molecular genetics of neurogenerative prion diseases such as scrapie, Creutzfeldt–Jakob disease, and "mad cow disease".[3]

Key Information

Life and career

[edit]

Charles Weissmann was born in 1931 in Budapest, and grew up between Zurich and Rio de Janeiro.[4] Weissmann went to University of Zurich and obtained his MD in 1956 and Ph.D. in Organic Chemistry in 1961. In 1978, Weissmann co-founded the biotech company Biogen in Geneva. Biogen is considered one of the pioneers of the biotechnology industries. Weissmann was director of the Institute for Molecular Biology in Zurich, President of the Roche Research Foundation and co-founder and Member of the Scientific Council of Biogen. He was Chairman of the Department of Infectology, Scripps Florida until 2011.[5]

He won several awards, including the Otto Warburg Medal (1980) and the Scheele Award (1982). A member of the American Society for Biochemistry and Molecular Biology and the Deutsche Akademie der Naturforscher Leopoldina he was also a Foreign Associate of the U.S. National Academy of Sciences, the Royal Society (UK) and the Pour le Mérite (Germany). On 16 May 2011, Weissmann became Doctor of Science Honoris Causa at New York University.

Weissmann died on 11 December 2025, at the age of 94.[6][7]

Awards

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Charles Weissmann

View on Grokipedia
from Grokipedia
Charles Weissmann was a Hungarian-Swiss molecular biologist renowned for being the first to clone and express the genes for interferon, enabling its large-scale production as a therapeutic agent, and for his pioneering contributions to the molecular biology of prion diseases. He co-founded Biogen, one of the earliest biotechnology companies, and his work advanced the understanding of how prions—protein-based infectious agents—undergo mutation, evolution, and Darwinian selection. Born in Hungary in 1931 to a Jewish family, Weissmann fled with his parents to Switzerland as an infant and later escaped Nazi-occupied Europe, spending part of his adolescence as a refugee in Rio de Janeiro before returning to Zurich after World War II. He earned his M.D. in 1956 and Ph.D. in organic chemistry in 1961 from the University of Zurich, followed by postdoctoral training with Severo Ochoa at New York University. Weissmann's early research included studies on bacteriophage lifecycles and site-specific mutagenesis techniques that predated modern genome editing tools. He established the Institute for Molecular Biology in Zurich and held positions at University College London before co-founding Biogen in 1978, where his interferon work supported the development of treatments for hepatitis C and certain cancers. In 2004, he joined the Scripps Research Institute in Florida as one of its inaugural faculty members, chairing the Infectology Department until his retirement in 2012 and continuing to lead influential prion research. A Fellow of the Royal Society since 1983 and a Foreign Associate of the U.S. National Academy of Sciences, Weissmann received numerous honors, including the Gabor Medal for his interferon cloning, the Royal Society GlaxoSmithKline Prize for prion research, and the Robert Koch Gold Medal. He passed away in Switzerland on December 11, 2025, at the age of 94.

Early Life and Education

Birth and Family Background

Charles Weissmann was born on 14 October 1931 in Budapest, Hungary, into a Jewish family. 80405-9) His Hungarian origins shaped his early heritage, though he later acquired Swiss citizenship and became widely recognized as a Hungarian-Swiss molecular biologist. Shortly after his birth, his family relocated to Zurich. This immediate family background reflected the broader context of Hungarian-Jewish roots amid the turbulent period leading up to World War II. 80405-9)

Childhood and Migration

Charles Weissmann's early childhood was spent in Zurich, Switzerland, following his family's relocation there shortly after his birth in 1931. In 1940, out of fear of the Third Reich and Nazi persecution, the family emigrated to Rio de Janeiro, Brazil. This move resulted in an upbringing divided between Zurich and Rio de Janeiro, exposing him to diverse cultural environments during his formative years. He spent his adolescence in Rio de Janeiro before returning to Zurich with his parents after the Second World War. Weissmann later returned to Zurich for higher education.

Academic Training

Charles Weissmann pursued his higher education at the University of Zurich, studying medicine and organic chemistry. He earned his Doctor of Medicine (MD) degree in 1956 and his Doctor of Philosophy (Ph.D.) in Organic Chemistry in 1961 from the University of Zurich. After completing his doctoral studies, Weissmann relocated to New York University School of Medicine in the United States for further training, where he shifted his focus to the emerging field of molecular biology. This postdoctoral period represented a pivotal transition in his academic path from organic chemistry to molecular approaches in biological research.

Scientific Career

Early Research and Academic Positions

Charles Weissmann began his independent research career at the University of Zurich following his PhD in organic chemistry in 1961, transitioning from organic chemistry to molecular biology. His early work centered on the replication mechanisms of RNA bacteriophages, particularly the Qβ phage, where he investigated the enzymatic synthesis of viral RNA and demonstrated that purified phage RNA could be infectious in vitro. During the 1960s, he held positions as an assistant and later as Privatdozent at the University of Zurich, building his research group and contributing to the emerging field of molecular virology. These roles laid the foundation for his subsequent appointment as professor and leadership positions at the institution.

Leadership at University of Zurich

Charles Weissmann was appointed professor extraordinarius of molecular biology at the University of Zurich in 1967 and promoted to professor ordinarius (full professor) in 1970, holding the position until his retirement in 1999. He also served as director of the newly founded Institute of Molecular Biology at the University of Zurich from 1967 until 1999, providing over three decades of leadership to the institution he established. His long-term directorship of the Institute of Molecular Biology helped build its foundation as a dedicated center for research in the field. Weissmann further contributed to the university's institutional resources by assigning the patent for recombinant alpha interferon production to the University of Zurich, generating licensing revenues amounting to several million Swiss francs. In addition, he established the Ernst Hadorn Foundation at the university, enabling the creation of an endowed professorship in molecular biology.

Biotechnology Ventures and Biogen

Charles Weissmann co-founded Biogen in 1978, one of the earliest and most influential biotechnology companies, alongside other prominent molecular biologists including Nobel laureates Walter Gilbert and Phillip Sharp. Initially established in Geneva, the company later relocated key operations to Cambridge, Massachusetts, and focused on applying recombinant DNA techniques to develop therapeutic proteins. As a co-founder, Weissmann played a pivotal role in directing Biogen toward the commercial application of molecular biology, particularly through his expertise in interferon research. His group at the University of Zurich was commissioned by Biogen to clone human interferon cDNA, building on foundational interferon work to enable large-scale production. In late 1979, Weissmann achieved the first successful cloning and expression of recombinant alpha interferon, a landmark accomplishment that allowed the production of biologically active interferon in sufficient quantities for therapeutic use. This breakthrough directly facilitated Biogen's early product development efforts, translating academic discoveries into commercially viable pharmaceuticals and establishing the company as a leader in the emerging biotechnology industry. Weissmann's contributions helped pioneer the field of recombinant therapeutics, demonstrating the potential of genetic engineering to create treatments for viral infections and certain cancers.

Later Career at Scripps Research Institute

In 2004, Charles Weissmann joined the Scripps Research Institute's Florida campus as chairman of the Department of Infectology, becoming one of the institution's first major scientific hires as the campus launched. He was recruited to provide leadership for the department and to help attract other eminent researchers to the Palm Beach County facility. Weissmann continued his research on infectious pathogens, including those causing malaria and tuberculosis, while maintaining a strong focus on prion diseases such as mad cow disease and Creutzfeldt-Jakob disease. During his tenure through 2012, Weissmann led a research team that advanced understanding of prions as infectious agents. His group demonstrated that prions can undergo evolution, mutation, and Darwinian selection in cultured cells despite lacking a nucleic acid genome. He recruited specialists in genetics, cell biology, and mouse biology to support these investigations and emphasized the development of innovative methods for probing and perturbing genetic material to elucidate its role in health and disease. Weissmann retired from his position as chairman of the Department of Infectology in 2012.

Major Scientific Contributions

Pioneering Work on Interferon

Charles Weissmann led the pioneering effort to clone and express human type I interferon cDNAs at the University of Zürich. Beginning in 1978, his team focused on human leukocyte interferon (IFN-α), utilizing mRNA from Sendai virus-induced human buffy coat leukocytes and developing complementary DNA through established molecular techniques. By 1979, they obtained positive clones via a hybrid-selection assay involving plasmid hybridization, elution of mRNA, and microinjection into Xenopus oocytes followed by antiviral testing. In early 1980, the group demonstrated that a cloned IFN-α cDNA directed the synthesis of a polypeptide exhibiting authentic human leukocyte interferon activity in Escherichia coli extracts, confirmed by pH resistance, species specificity, and antibody neutralization. This marked the first unambiguous expression of functional recombinant human IFN-α in bacteria. The achievement, published in Nature in 1980, enabled large-scale production of homogeneous recombinant interferon, overcoming limitations of natural extraction from blood cells. It provided definitive proof that interferon’s biological activities originated from the molecule itself and revealed the existence of multiple distinct IFN-α genes. This work had profound technical significance by advancing eukaryotic gene cloning methods and facilitating structural analysis of interferon genes. Recombinant IFN-α produced through these methods became a cornerstone of antiviral therapies, notably for hepatitis C treatment until 2014, and influenced certain cancer treatments. The research catalyzed broader cytokine discovery efforts, as the cloning of interferon genes inspired identification of other cytokines. Biogen, co-founded by Weissmann, commercialized the recombinant interferon developed from this breakthrough.

Prion Disease Research

Charles Weissmann's entry into prion disease research leveraged his established expertise in molecular biology to elucidate the genetic and molecular basis of these fatal neurodegenerative disorders. His group's landmark contributions centered on the prion protein (PrP) encoded by the Prnp gene and its essential role in prion propagation. In 1992, Weissmann and collaborators generated the first PrP knockout mice using gene targeting in embryonic stem cells. These mice developed normally, with no overt behavioral or morphological abnormalities, indicating that the cellular prion protein (PrP^C) is not required for normal neuronal development or function. Building on this, in 1993 the team demonstrated that PrP-deficient mice were completely resistant to intracerebral inoculation with mouse-adapted scrapie prions. Inoculated PrP null mice remained healthy for over 300 days, while wild-type controls succumbed to disease within approximately 150 days, providing direct genetic evidence that PrP expression is necessary for prion replication and pathogenesis. These findings constituted a critical validation of the protein-only hypothesis of prion diseases, showing that the infectious agent depends on host PrP for propagation rather than a conventional nucleic acid genome. Weissmann's subsequent studies used transgenic models to investigate prion strain variation and the molecular basis of species barriers to transmission, including the role of PrP sequence differences in restricting cross-species infectivity. Throughout his later career, particularly after joining the Scripps Research Institute in 2004, Weissmann continued to explore prion biology, focusing on mechanisms of PrP misfolding, neuronal toxicity, and potential interventions against prion diseases. His work on PrP knockout and transgenic mice has remained foundational for understanding prion neurodegenerative mechanisms and has influenced research into related protein-misfolding disorders.

Broader Impact on Molecular Biology

Charles Weissmann's methodological innovations profoundly influenced modern molecular biology, particularly through his pioneering development of reverse genetics and site-directed mutagenesis. Using the RNA bacteriophage Qβ as a model system, he established techniques for the precise modification of genetic sequences, enabling targeted studies of gene function and protein behavior that were previously unattainable. These approaches, along with his fundamental insights into RNA phage replication, became essential tools that transformed molecular genetics and facilitated detailed investigations across diverse biological systems. Weissmann is widely regarded as having laid much of the bedrock for contemporary molecular biology, with his work creating foundational methods that shaped subsequent research and applications in the field. His establishment of the Institute for Molecular Biology at the University of Zurich fostered a hub for innovative research and mentored numerous scientists who advanced the discipline further, ensuring his influence extended through generations. As a co-founder of Biogen, he also bridged academic discoveries to biotechnology, helping translate molecular insights into medical advancements and underscoring his broader legacy in linking basic science to therapeutic progress. His contributions collectively exerted a lasting impact on both biotechnology and neuroscience, where his methodological rigor and conceptual advances continue to inform studies of gene regulation, protein dynamics, and disease mechanisms at the molecular level.

Awards and Honors

Personal Life

Death and Legacy

Add your contribution
Related Hubs
User Avatar
No comments yet.